This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mithra Pharmaceuticals 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Christophe Marechal

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	4.4yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO

Christophe Marechal

7.6yrs

테뉴어

Mr. Christophe Maréchal has been the Chief Financial Officer of Mithra Pharmaceuticals SA since February 23, 2017 and also serves as its Co-Chief Executive Officer since March 5, 2024. Mr. Maréchal serves...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christophe Marechal	Co-CEO & CFO	7.6yrs	데이터 없음	데이터 없음
Xavier Paoli	COO & Co-CEO	less than a year	데이터 없음	데이터 없음
Graham Dixon	Chief Scientific Officer	5.2yrs	데이터 없음	데이터 없음
Alex Sokolowski	Head of Investor Relations	no data	데이터 없음	데이터 없음
Fanny Rozenberg	Secretary of the Board & General Counsel	no data	데이터 없음	데이터 없음
Fanny Storms	Compliance Officer	no data	데이터 없음	데이터 없음
Frederique Depraetere	Communication Director	no data	데이터 없음	데이터 없음
Catherine Lejeune	HR Director	no data	데이터 없음	데이터 없음
Jean-Manuel Fontaine	Chief Business Officer	3.7yrs	데이터 없음	0.000040% € 4.9
Jean-Michel Foidart	President of the Scientific Advisory Board & Executive Director	no data	€7.12k	0.029% € 3.6k
Christophe Saillez	Head of Global Regulatory Affairs	no data	데이터 없음	데이터 없음
Maud Jost	Head of Program & Project Management	no data	데이터 없음	데이터 없음

4.4yrs

평균 재임 기간

경험이 풍부한 관리: 0R91 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jean-Michel Foidart	President of the Scientific Advisory Board & Executive Director	8yrs	€7.12k	0.029% € 3.6k
Jacques Platieau	Independent & Non-Executive Director	1.7yrs	€25.00k	데이터 없음
Valerie Gordenne	Non-Executive Director	2.8yrs	€20.00k	0.042% € 5.1k

2.8yrs

평균 재임 기간

경험이 풍부한 이사회: 0R91 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

This company listing is no longer active

Mithra Pharmaceuticals 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Mithra Pharmaceuticals SA Announces CEO Changes

Mithra Appoints Christian Homsy as Chairman

Mithra Approves Board Appointments

Mithra Pharmaceuticals SA, Annual General Meeting, May 25, 2023

Less than half of directors are independent

High number of new directors

Recent updates

Forecast to breakeven in 2025

Forecast to breakeven in 2026

New major risk - Financial position

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Mithra Pharmaceuticals SA Announces CEO Changes

Mithra Pharmaceuticals SA to Report First Half, 2024 Results on Sep 26, 2024

Mithra Pharmaceuticals SA to Report Fiscal Year 2023 Results on Mar 08, 2024

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Market cap size

First half 2023 earnings released

New major risk - Negative shareholders equity

Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023

New major risk - Revenue and earnings growth

Mithra Pharmaceuticals SA has completed a Follow-on Equity Offering in the amount of €20 million.

Mithra Pharmaceuticals SA announced that it has received €20 million in funding from Armistice Capital, LLC

Forecast breakeven date pushed back to 2025

New minor risk - Market cap size

Mithra Announces New Positive Preclinical Data from Csf-1R Inhibitor Program

Mithra Appoints Christian Homsy as Chairman

Mithra Approves Board Appointments

Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Mithra Pharmaceuticals SA to Report Fiscal Year 2022 Final Results on Apr 18, 2023

Mithra Pharmaceuticals SA, Annual General Meeting, May 25, 2023

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

First half 2022 earnings released: €0.69 loss per share (vs €1.28 loss in 1H 2021)

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mithra Pharmaceuticals SA announced that it expects to receive €23.500005 million in funding

High number of new directors

Full year 2021 earnings: Revenues miss analyst expectations

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

Forecast to breakeven in 2022

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Full year 2020 earnings released: €2.25 loss per share (vs €0.70 loss in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day high: €23.33

Investor sentiment improved over the past week

Mithra and Searchlight Pharma Announces Nextstellis Approval in Canada

Mithra Pharmaceuticals SA to Report Fiscal Year 2020 Results on Mar 09, 2021

Mithra Announces Executive Changes

Mithra Pharmaceuticals SA, Annual General Meeting, May 20, 2021

New 90-day high: €18.50

New 90-day low: €16.53

New 90-day low: €16.89

New 90-day low - €17.08

Mithra Pharmaceuticals SA has completed a Follow-on Equity Offering in the amount of €64.999988 million.

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간